Back to all studies
🎗️
Phase 3
Oncology
in-person
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Sponsored by Novartis Pharmaceuticals
Compensation
$500–$2,500
Duration
3 months
Location
Nationwide
About this study
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).
Who can participate
- • Adults aged 18–99
- • All genders welcome
- • Diagnosed with or experiencing early breast cancer
- • Able to attend in-person clinic visits
What's included
- • Compensation up to $2,500
- • All study-related medical care at no cost
- • Lab work, screenings, and physician consultations
- • Study medication or treatment provided
IRB-approved study. Free to apply. Your information is kept confidential.
Ready to Find a Paid Study?
Join over 100,000 people who have been matched with clinical studies. It's free, fast, and could change your life.